BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29216889)

  • 21. Dysregulation of adenosine kinase isoforms in breast cancer.
    Shamloo B; Kumar N; Owen RH; Reemmer J; Ost J; Perkins RS; Shen HY
    Oncotarget; 2019 Dec; 10(68):7238-7250. PubMed ID: 31921385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.
    Ciardiello C; Leone A; Lanuti P; Roca MS; Moccia T; Minciacchi VR; Minopoli M; Gigantino V; De Cecio R; Rippa M; Petti L; Capone F; Vitagliano C; Milone MR; Pucci B; Lombardi R; Iannelli F; Di Gennaro E; Bruzzese F; Marchisio M; Carriero MV; Di Vizio D; Budillon A
    J Exp Clin Cancer Res; 2019 Jul; 38(1):317. PubMed ID: 31319863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
    Annis MG; Ouellet V; Rennhack JP; L'Esperance S; Rancourt C; Mes-Masson AM; Andrechek ER; Siegel PM
    Breast Cancer Res; 2018 Jan; 20(1):9. PubMed ID: 29382358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma.
    Liu M; Zhao J; Chen K; Bian X; Wang C; Shi Y; Wang JM
    Int Immunopharmacol; 2012 Nov; 14(3):283-8. PubMed ID: 22863814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
    Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
    J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
    Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
    J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of the N-formyl Peptide receptors in scleroderma fibroblasts fosters the switch to myofibroblasts.
    Rossi FW; Napolitano F; Pesapane A; Mascolo M; Staibano S; Matucci-Cerinic M; Guiducci S; Ragno P; di Spigna G; Postiglione L; Marone G; Montuori N; de Paulis A
    J Immunol; 2015 Jun; 194(11):5161-73. PubMed ID: 25917089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
    Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
    Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
    Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
    PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.
    Carriero MV; Bifulco K; Ingangi V; Costantini S; Botti G; Ragone C; Minopoli M; Motti ML; Rea D; Scognamiglio G; Botti G; Arra C; Ciliberto G; Pessi A
    Sci Rep; 2017 May; 7(1):1312. PubMed ID: 28465589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted agents and immunotherapies: optimizing outcomes in melanoma.
    Luke JJ; Flaherty KT; Ribas A; Long GV
    Nat Rev Clin Oncol; 2017 Aug; 14(8):463-482. PubMed ID: 28374786
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.